In the BioHarmony Drug Report Database

"Preview" Icon

Margetuximab

Margenza (margetuximab) is an antibody pharmaceutical. Margetuximab was first approved as Margenza on 2020-12-16. The pharmaceutical is active against receptor tyrosine-protein kinase erbB-2.

 

Trade Name

 

Margenza
 

Common Name

 

margetuximab
 

ChEMBL ID

 

CHEMBL2364649
 

Indication

 

 

Drug Class

 

Monoclonal antibodies: chimeric, tumors as target

Image (chem structure or protein)

Margetuximab structure rendering